Patents by Inventor Mike Breider

Mike Breider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
    Publication number: 20220003749
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Application
    Filed: April 1, 2021
    Publication date: January 6, 2022
    Applicant: CELGENE CORPORATION
    Inventors: Matthew William Burnell TROTTER, Patrick HAGNER, Courtney G. HAVENS, Rajesh CHOPRA, Anita GANDHI, Anke KLIPPEL, Maria Yinglin WANG, Mike BREIDER, Suzana Sturlini COUTO, Yan REN, Paul HOLLENBACH, Kyle MACBETH
  • Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
    Patent number: 10996215
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 4, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Matthew William Burnell Trotter, Patrick Hagner, Courtney G. Havens, Rajesh Chopra, Anita Gandhi, Anke Klippel, Maria Yinglin Wang, Mike Breider, Suzana Sturlini Couto, Yan Ren, Paul Hollenbach, Kyle Macbeth
  • METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
    Publication number: 20190004033
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Application
    Filed: April 5, 2018
    Publication date: January 3, 2019
    Inventors: Matthew William Burnell TROTTER, Patrick HAGNER, Courtney G. HAVENS, Rajesh CHOPRA, Anita GANDHI, Anke KLIPPEL, Maria Yinglin WANG, Mike BREIDER, Suzana Sturlini COUTO, Yan REN, Paul HOLLENBACH, Kyle MACBETH
  • METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
    Publication number: 20160313300
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Application
    Filed: December 5, 2014
    Publication date: October 27, 2016
    Inventors: Matthew William Burnell Trotter, Patrick Hagner, Courtney G. Havens, Rajesh Chopra, Anita Gandhi, Anke Klippel, Maria Yinglin Wang, Mike Breider, Suzana Sturlini Couto, Yan Ren, Paul Hollenbach, Kyle MacBeth